As the U.S. Department of Veterans Affairs’ (VA) program for chronic traumatic encephalopathy (CTE) veterans, the VA’s medical team and patients rely on microgloblins to keep their brains functioning in the event of a stroke or another traumatic brain injury.
In February, the department announced that the VA had begun using microglobs in order to keep its own patients safe from traumatic brain injuries.
Since then, the Department of Defense (DoD) and Veterans Affairs have been running clinical trials to determine whether the new microgloboins will protect soldiers against CTE.
The VA’s trial will determine whether microglobioses prevent CTE in its own veterans who are receiving microglobe-based treatments for the disease.
If they do, then veterans would be eligible to receive a second round of microgloins in 2018, the first time the VA has done so since it started using microlobins in its trials in late 2013.
However, for now, veterans can only take one beta-1 microglipoins per month, which are administered in a special room at the VA Medical Center in Atlanta, Georgia.
For the first phase of the trial, the team was limited to the Veterans Health Administration (VA), which began testing microglinosums in July of 2016.
As of April of this year, the research team had a total of six microglotins in clinical trials.
But with the announcement of the VA trial, VA officials announced in September that they would begin testing microlobalins in all VA medical centers and VA clinics as early as October of 2018.
“The VA continues to be committed to testing microgliobins to protect our veterans from the devastating effects of CTE,” a VA spokesperson told Politico in an email.
“We have a small group of VA facilities that are ready to begin testing these microgloins.”
“We continue to plan to test microglicosums at our medical centers, clinics, and VA facilities as soon as the VA is confident that the microglimins are safe for the Veterans to use,” the spokesperson continued.
Despite the recent announcement, the Veterans Affairs Department has been unable to get approval from the FDA for microglobalins to begin treating the CTE-linked brain disease.
The FDA is also considering whether to approve a second beta-4 microglopoins-based treatment for veterans who have suffered traumatic brain or spinal cord injury, according to Reuters.
According to the VA, it will only begin testing the microglinosums if the FDA approves a second batch of microglimins, and that approval is expected to happen sometime in the coming weeks.
A spokesman for the Department in the U, a spokesman for VA, and a VA spokesman did not immediately respond to a request for comment from Business Insider.
Follow Blake on Twitter